%0 Journal Article
%T Hodgkin¡¯s lymphoma in a patient on adalimumab treatment for psoriasis
%A Ahmed Abdullah Alhumidi
%A Alanoud Alyousef
%A Albatool Alamari
%A Fahad Mohammed Alsaif
%A Leena Zeitouni
%A Mohammed Ayesh Zayed
%A Nouf Alballa
%J Archive of "AME Case Reports".
%D 2018
%R 10.21037/acr.2018.12.01
%X Adalimumab is a human monoclonal antibody which targets tumor necrosis factor (TNF)-alpha. It is produced by recombinant DNA technology, using a mammalian cell expression system and is widely-known to treat a number of immune-mediated conditions, including psoriasis. There has been a growing concern regarding the possible association between TNF-alpha inhibitors and malignancy. In this case report, we describe the case of a 20-year-old woman, known to have been suffering from chronic plaque psoriasis for 12 years, and who developed Hodgkin¡¯s lymphoma within five weeks of beginning adalimumab treatment
%K Adalimumab
%K Hodgkin¡¯s lymphoma
%K psoriasis
%K tumor
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327155/